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Acute myeloid leukemias (AMLs) result
from multiple genetic alterations in he-
matopoietic stem cells. We describe a
novel t(12;18)(p13;q12) involving ETV6
in a patient with AML. The translocation
resulted in overexpression of SETBP1
(18q12), located close to the breakpoint.
Overexpression of SETBP1 through ret-
roviral insertion has been reported to
confer growth advantage in hematopoi-
etic progenitor cells. We show that
SETBP1 overexpression protects SET
from protease cleavage, increasing the
amount of full-length SET protein and
leading to the formation of a SETBP1–
SET-PP2A complex that results in PP2A
inhibition, promoting proliferation of the
leukemic cells. The prevalence of
SETBP1 overexpression in AML at diag-
nosis (n  192) was 27.6% and was asso-
ciated with unfavorable cytogenetic
prognostic group, monosomy 7, and
EVI1 overexpression (P < .01). Patients
with SETBP1 overexpression had a sig-
nificantly shorter overall survival, and
the prognosis impact was remarkably
poor in patients older than 60 years in
both overall survival (P  .015) and
event-free survival (P  .015). In sum-
mary, our data show a novel leukemo-
genic mechanism through SETBP1 over-
expression; moreover, multivariate
analysis confirms the negative prognos-
tic impact of SETBP1 overexpression in
AML, especially in elderly patients,
where it could be used as a predictive
factor in any future clinical trials with
PP2A activators. (Blood. 2010;115:
615-625)
Introduction
Acute myeloid leukemia (AML) is a heterogeneous clonal
malignancy that predominantly affects middle-aged and elderly
adults. The disease is characterized by a differentiation block in
early progenitors, which leads to the accumulation of immature
cells in bone marrow (BM) and peripheral blood. In recent
years, several genetic markers with prognostic impact in AML
have been identified, leading to a better understanding of the
biology of this disease and, in some cases, providing targets for
molecular therapies.1 Cytogenetic aberrations have been re-
ported as the most important prognostic factors for survival and
response to therapy in AML, allowing the identification of
molecular markers that have greatly advanced our understand-
ing of leukemogenesis2; nevertheless, the nature of alterations
responsible for initiation or progression of the disease is mostly
unknown. Recent attempts to identify initiating or progression
mutations by extensively resequencing tyrosine kinase genes,3,4
expression profiling studies,5-7 array-based comparative genomic
hybridization and/or single nucleotide polymorphism,8-11 and
even by unbiased whole-genome sequencing,12 confirm that
AML results from multiple genetic alterations in hematopoietic
stem cells, and suggest that we have not yet discovered most of
the relevant aberrations that contribute to the pathogenesis of
this disease.
The ETV6 gene (12p13) encodes a transcription factor
frequently rearranged in both myeloid and lymphoid leukemias.
Translocation breakpoints are distributed throughout the gene,
and ETV6 contributes to the pathogenesis of leukemia by
diverse molecular mechanisms that are only partially under-
stood. In most cases, the translocations result in the generation
of in-frame fusion genes between different domains of ETV6
and partner genes encoding either kinases or transcription
factors.13 However, in some cases involving the 5 end of ETV6,
functionally significant fusions could not be detected and a
different leukemogenic mechanism has been described: the
deregulation of the expression of oncogenes located close to the
breakpoints.13,14 This molecular mechanism, which has been
described mainly in lymphoid leukemias and lymphomas, is an
uncommon mechanism in myeloid leukemias, although some
examples have been reported.13,15
Here, we describe a novel leukemogenic mechanism in a patient
with AML and a t(12;18)(p13;q12) involving ETV6. The transloca-
tion resulted in overexpression of SETBP1 (18q12), located close
to the breakpoint. We show that SETBP1 overexpression protects
SET from protease cleavage, increasing the amount of full-length
SET protein and leading to the formation of a SETBP1–SET-PP2A
complex that results in PP2A inhibition and therefore promotes the
proliferation of leukemic cells. Moreover, we show that SETBP1
overexpression is a recurrent molecular event associated with a
significantly shorter overall survival (OS) in AML, especially in
elderly patients.
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Methods
Case reports
A 76-year-old white man was diagnosed with myelodysplastic syndrome.
Disease evaluation of the patient 3 years after the diagnosis showed anorexia,
perspiration, and loss of 7 kg. Laboratory findings at this moment were: hemo-
globin 10.9 g/dL, white blood cell count 38.2 109/L with 55% blasts, and
platelet count 251 109/L; BM aspirate was hypercellular, showing 80% blasts.
Flow cytometry showed positivity for CD34, CD13, CD33, CD11b, and
HLA-DR. The patient was diagnosed as AML-M5. Karyotype showed 2 clones:
46,XY,t(12,18)(p13;q12)[77%]/47,idem,19[23%]. The patient received stan-
dard induction chemotherapy for 2 months and had partial remission at the next
evaluation. Laboratory findings showed hemoglobin 9.9 g/dL, white blood cell
count 25.5 109/L with 32% blasts, and 260 109/L platelets. Karyotype at
this time was: 46,XY,t(12,18)(p13;q12)[24%]/46,XY[76%]. The patient relapsed
2 months later and eventually died. Karyotype at relapse showed the 2 clones
detected at diagnosis: 46,XY,t(12,18)(p13;q12)[32%]/47,idem,19[68%]. All
samples were taken anonymously, and the study was approved by the Institu-
tional Committee of the University of Navarra.
FISH
Bacterial artificial chromosomes obtained from the Roswell Park Cancer
Institute (Buffalo, NY) were used to map the breakpoints in the patient
samples. The order of the probes is centromere-418C2-96B19-434C1-
telomere (12p13), and centromere-840B16-937P23-252G8-941F5-
telomere (18q12). Probes were labeled with SpectrumGreen-dUTP or
SpectrumOrange-dUTP. Centromeric probes for chromosomes 12 and 18
were also used in fluorescence in situ hybridization (FISH) experiments.
FISH was performed as previously described.14
RACE
3- and 5-rapid amplification of cDNA ends (RACE)–polymerase chain
reaction (PCR) were performed from total RNA using the GeneRacer kit
(Invitrogen). 3RACE-PCR (94°C 30 seconds, 72°C 2 minutes 30 seconds,
5 cycles; 94°C 30 seconds, 70°C 2 minutes 30 seconds, 5 cycles; 94°C
30 seconds, 64°C 30 seconds, 68°C 2 minutes 30 seconds, 25 cycles) was
performed using the primer ETV6-EX1F (exon 1) and a reverse primer
from the kit. Nested PCR was performed under the same conditions with
ETV6-EX1Fn (exon 1). Products were cloned and sequenced. For 5RACE,
the same PCR conditions were used, with primers ETV6-EX3R and
ETV6-EX3Rn (exon 3; supplemental Table 1, available on the Blood
website; see the Supplemental Materials link at the top of the online article).
Nucleic acid isolation and RT-PCR
Total DNA was isolated using the QIAmp DNA minikit, and total RNA
using the RNeasy minikit (QIAGEN). cDNA was synthesized with
SuperScriptIII Reverse Transcriptase (Invitrogen). Reverse-transcribed
(RT)–PCR reactions were carried out with Ampli-Taq Gold DNA Polymer-
ase (Applied Biosystems) after optimizing cycling conditions for each
primer pair. To confirm the presence of the fusion products, RT-PCR
reactions were performed on patient RNA with primers ETV6-EX1F2,
and CR18-B and CR18-E (supplemental Table 1). Products were cloned
and sequenced.
Real-time RT-PCR
Quantification of the expression of SETBP1, SET, and ETV6 was performed
using TaqMan Gene Expression Assays (Applied Biosystems) specific for
each gene. GAPDH was used as internal control. A gene was considered
overexpressed if its expression value was higher than the cut-off value
established for each gene (mean  5 SD), defined by the analysis of
10 normal BM samples.
Cell culture and transfection
HEL, K562, 32Dcl3, and HEK293 cell lines were grown at 37°C in a 5%
CO2 atmosphere. HEK293 cells were maintained in Dulbecco’s minimum
essential medium, HEL and K562 in RPMI-1640 (Invitrogen), and 32Dcl3
in RPMI 1640  10% conditioned medium of cell line WEHI-3B (DSM
ACC 26). Media were supplemented with 10% fetal bovine serum,
penicillin G (100 U/mL), and streptomycin (0.1 mg/mL). For transfection
experiments, HEK293 cells were seeded into 10-cm dishes and transfected
with 60 L of Lipofectamine2000 (Invitrogen) and 12 g of the plasmids
expressing SETBP1(SKI homologous region [SHR])–V5, SETBP1-GFP,
SETBP1(SETBD)–GFP, SET-GFP, or empty vector as control. HEL and
32Dcl3 cells were seeded in culture flasks and transfected using the
Nucleofector System (solution V; protocol X-005 for HEL, and E-032 for
32Dcl3; Amaxa), with 4 g of plasmidic vectors or 75nM SET siRNA pool
designed and synthesized by Dharmacon RNA Technologies.
Plasmids
Human SET cDNA was obtained by RT-PCR from K562 RNA using an
upstream primer containing an EcoRI site followed by the first 19 nucleo-
tides of SET cDNA, and a downstream primer containing the last
21 nucleotides of SET linked to a BamHI site. The EcoRI/BamHI digested
PCR product was subcloned into the pEGFP-C2 vector leading to the
pEGFPC2-SET construct. Human SETBP1 cDNA was obtained by RT-PCR
from peripheral blood and subcloned into the vector pEGFP-C2 through
XhoI/SalI sites, resulting in the pEGFPC2-SETBP1 construct. The region
from amino acids 1167 to the end of SETBP1 was obtained by digestion
from the pEGFPC2-SETBP1 construct and subcloned into the vector
pEGFP-C2 through HindIII/SacII sites, resulting in the pEGFPC2-
SETBP1(SETBD) construct. The region from amino acids 449 to amino
acids 857 of SETBP1 was obtained by PCR from the pEGFPC2-SETBP1
and subcloned into the pcDNA3.1V5/His vector, leading to the
pcDNA3.1V5/His-SETBP1(SHR). All cloning procedures were verified by
sequencing.
Immunoprecipitation and Western blotting
Cells were lysed in 100 L of lysis buffer containing 1% Triton X-100 and
protease inhibitors (Complete Mini; Roche Diagnostics). After incubation
on ice (30 minutes), protein extracts were clarified (12 000g, 15 minutes,
4°C), denatured, and subjected to sodium dodecyl sulfate-polyacrylamide
gel electrophoresis and Western blot. Antibodies used were goat polyclonal
anti-SET (Santa Cruz Biotechnology), mouse monoclonal anti-PP2A (clone
1D6, Upstate), rabbit monoclonal anti-PP2AY307 (Epitomics), rabbit poly-
clonal anti-GFP (Santa Cruz Biotechnology), and mouse monoclonal
anti-tubulin (Sigma-Aldrich). For immunoprecipitation, lysates were
precleared (1 hour, 4°C) on a rotating wheel and immunoprecipitated with
antibody-bound protein G-Sepharose (8 hours, 4°C). After washings,
immunoprecipitations were subjected to sodium dodecyl sulfate-
polyacrylamide gel electrophoresis and Western blot. Proteins were de-
tected with the appropriate secondary antibodies by chemiluminescence
(ECL kit; GE Healthcare).
Proliferation assay, viability, and total cell counts
Cell proliferation was measured in triplicate wells by 3-(4,5 dimethylthiazol-
2-yl)-5-(3-carboxymethoxyphenyl-2-(4-sulfophenyl)-2H-tetrazolium (MTS)
assay in 96-well plates using the CellTiter 96 AQueous One Solution Cell
Proliferation Assay (Promega). Cell viability and total counts were
measured in triplicate with the Nucleocounter (Biogen), and the results
confirmed by Trypan Blue method.
PP2A assays
PP2A assays were performed with cell lysates (50 g) using a PP2A
immunoprecipitation phosphatase assay kit (Millipore) as previously de-
scribed,16 except that we added the protease inhibitor cocktail Complete
(Roche Diagnostics) to the protein extraction mix.
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Statistical analysis
Statistical analyses were performed using SPSS 15 for windows (SPSS
Inc). OS was defined as the time from diagnosis to death of any cause or end
of follow-up. Disease-free survival (DFS) was defined as the time from
complete remission until relapse or death. Event-free survival (EFS) was
defined as the time from diagnosis until first event, in which failure to
achieve complete remission, relapse, death, or end of follow-up were
considered events. OS, DFS, and EFS were determined according to the
Kaplan-Meier method and survival comparisons were done with the
log-rank test if proportional hazard assumption was fulfilled, and Breslow
otherwise. The Cox proportional hazards model was used to assess patient
outcome for patient-stratified groups of age. The hazard model was adjusted
taking into consideration relevant parameters that included cytogenetic
group, complete remission, and SETBP1 overexpression. Good risk and
intermediate risk were analyzed together because of the small number of
patients with good-risk cytogenetics. A P value less than .05 was considered
statistically significant.
Bioinformatics analysis of the SETBP1 proximal promoter
Analysis of the proximal promoter of SETBP1 was performed with
MotifScanner,17-19 which scans DNA sequences with precompiled motif
models. This algorithm assumes that motifs are hidden in a noisy
background sequence represented by a higher-order Markov model. The
motif models of transcriptional factors were obtained from the public
version of Jaspar and Transfac databases. The proximal promoter of
SETBP1 was defined as 3000 bp upstream the transcription start site and
was extracted from Ensembl database release 53.
Results
SETBP1 (18q21) is overexpressed in a patient with a
translocation t(12;18) involving ETV6
Karyotype at diagnosis of a patient with AML-M5 secondary to
myelodysplastic syndrome was 46,XY,t(12,18)(p13;q12)/
47,idem,19. FISH showed that the breakpoint on 12p13 was
located between exons 2 and 3 of ETV6 (supplemental Figure 1).
To identify the fusion partner of ETV6, RACE-PCR experiments
were performed on RNA from BM of the patient. 3RACE-PCR
identified 2 clones containing ETV6 exon 2 followed by sequences
that overlapped with the human cDNA clone BC051727 (Mamma-
lian Gene Collection Program Team) located in chromosome 18
(Figure 1). Alignment of these sequences to the human genome did
not reveal the presence of a known gene, but the novel sequences
were split into segments that were flanked by consensus splice
donor and acceptor sites. This indicated that these sequences could
be part of a novel gene, whose exact identity and complete cDNA
sequence were not further analyzed. Because the complete tran-
script is currently unknown, the different exons identified in this
sequence were arbitrarily named as follows: fusion transcript 1,
ETV6-exon-1 ETV6-exon-2 exon-“a” exon-“b”; fusion tran-
script 2, ETV6-exon-1ETV6-exon-2 exon-“c” exon-“d” exon-
“e.” Stop codons were found in the 3 different reading frames for exons
Figure 1. Genetic characterization of a patient with AML-M5 and a t(12;18)(p13;q12) involving ETV6. (A) FISH analysis indicating the breakpoint on 18q12: probe
RP11-252G8 (green) splits and hybridizes in both der(18) and der(12). (B) Analysis by quantitative RT-PCR of the SETBP1 expression in samples of the patient at
diagnosis, posttreatment control, and relapse. (C) RACE results showing the 2 different fusion transcripts detected. Sequences from ETV6 are in italics; the putative exons
from chromosome 18 are underlined.
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“b” and “e,” indicating that these exons are part of a noncoding
transcript. The presence of these 2 fusions was confirmed by RT-PCR,
cloned, and sequenced (data not shown). Fusion transcripts predicted, in
both cases, truncated proteins resulting from the presence of premature
stop codons (Figure 1). Besides, the predicted new proteins showed no
homology with any known proteins. In these novel sequences, we found
no microRNAs that could be deregulated as a consequence of the
translocation. 5RACE-PCR failed to find any reciprocal fusion tran-
script. Taken together, these data suggest that no functionally significant
fusion transcripts were generated by the translocation.
To confirm the position of the breakpoint on chromosome 18,
bacterial artificial chromosomes located at 18q12 were used as
probes in FISH experiments. Analysis on BM cells of the patient
showed that one signal hybridized to the normal chromosome 18,
and the other split and hybridized to both der(18) and der(12)
(Figure 1). FISH showed that the breakpoint was located 5 and
close to the SETBP1 gene. Activation of SETBP1 expression by
retroviral integration in hematopoietic progenitor cells has been
reported to confer a growth advantage leading to clonal expan-
sion.20 Knowing that SETBP1 was close to the breakpoint in the
t(12;18)(p13;q12) and taking into account that ectopic expression
of oncogenes is a mechanism involved in leukemia, we analyzed
the expression of SETBP1 by real-time PCR (quantitative RT-PCR)
in this patient, and we found that SETBP1 was overexpressed at
diagnosis and in the posttreatment samples (Figure 1).
Ectopic expression of SETBP1 leads to increased full-length
SET protein levels
SETBP1 has been reported to specifically interact with the protein
SET,21 a potent inhibitor of protein phosphatase 2A (PP2A). To
assess whether the ectopic expression of SETBP1 affects SET
protein levels, HEK293 cells were transiently transfected with
SETBP1-GFP. We found that levels of the 39-kDa full-length form
of SET were strongly induced; moreover, an important decrease in
the levels of low molecular weight forms of SET was observed. As
controls, ectopic expression of the SETBP1-GFP protein was
detected by anti-GFP (Figure 2A) and quantitative RT-PCR (supple-
mental Figure 2A). Analysis by fluorescence microscopy of
SETBP1-GFP–transfected HEK293 cells confirmed a predomi-
nantly nuclear location of SETBP1 (supplemental Figure 2B).
Figure 2. Ectopic expression of SETBP1 induces increased full-length SET levels and inhibits PP2Ac. (A) Western blot showing endogenous SET expression in
HEK293 cells transfected with SETBP1-GFP, an empty vector as a control, or nontransfected cells. (B) Analysis by Western blot showing SET in HEK293 cells transfected with
different regions of SETBP1. SHR indicates SKI homologous region; and SETBD, SET binding domain. (C) Western blot and densitometry analysis showing the effect of
ectopic SETBP1 over PP2A expression in HEK293 cells. (D) Western blot and densitometry analysis showing the effect of ectopic SETBP1 over PP2A phosphorylation levels
of the tyrosine-307. (E) PP2A phosphatase assay in HEK293 cells transfected or not with SETBP1.
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To assess the origin of the proteins of different sizes detected by
anti-SET antibodies, HEK293 cells were transfected with SET-
GFP and harvested at different times. Full-length SET-GFP protein
of approximately 67 kDa could be detected by Western blot 9 hours
after transfection, and 2 additional bands of lower molecular
weight appeared gradually, together with the full-length form
(supplemental Figure 2C). Taking into account the molecular
weight of GFP, these bands would correspond to the endogenous
short SET forms (Figure 2A). Because SET-GFP is expressed from
a cDNA sequence, and alternative splicing cannot take place in the
absence of intronic sequences, these results suggest that the
endogenous SET protein of 39 kDa is cleaved by proteases,
resulting in truncated proteins with distinct sizes.
To analyze the region of SETBP1 that is critical to induce this
effect, we transfected HEK293 cells with the vector pcDNA3.1-
SETBP1(SHR)-V5, which expresses an internal region of SETBP1
that includes the SHR, and with the vector pEGFPC2-
SETBP1(SETBD), expressing the carboxy-terminal region of
SETBP1 that includes the SET binding domain (SETBD). We used
HEK293 cells transfected with SETBP1-GFP as positive control,
with the empty vector as negative control. We found similar results
transfecting with SETBP1-GFP and with SETBD-GFP; however,
no effects were observed with SETBP1(SHR)-V5, indicating that
the region containing SETBD is critical (Figure 2B). Taken
together, these results suggest that SETBP1 has a major effect on
the 39-kDa form of SET, probably increasing its levels by
impairing protease activity on the full-length SET protein.
SETBP1 inhibits PP2A activity through tyrosine
phosphorylation of its catalytic subunit
We next investigated the effect of SETBP1 overexpression on the
PP2A protein. Expression levels of the catalytic subunit of PP2A
(PP2Ac) were not affected in HEK293 cells transfected with
SETBP1-GFP, with respect to nontransfected cells (Figure 2C).
However, an increase in the phosphorylation of tyrosine-307 was
observed (Figure 2D). Of note, phosphorylation of tyrosine-307 is
responsible for more than 90% of the phosphatase activity of this
protein; indeed, it has been shown that PP2Ac is inactive when
tyrosine-307 is phosphorylated.22 These results suggest that ectopic
expression of SETBP1 leads to a reduced PP2A activity, which was
confirmed by a PP2A phosphatase assay (Figure 2E).
We next assessed whether the observations made in SETBP1-
transfected cells could be confirmed in the patient samples. As a
positive control for PP2A inactivation and SET overexpression,
protein extracts from K562 cells were included.23 The patient
showed higher phosphorylation of tyrosine-307 of PP2Ac in both
relapse and posttreatment samples, compared with normal donors.
We also observed increased SET protein levels, with good correla-
tion between protein and mRNA (Figure 3; supplemental Figure 3).
SETBP1 induces proliferation in HEL and 32Dcl3
To investigate the effect of SETBP1 on cell growth, the HEL cell
line (AML-M6) was chosen as a cellular model. An increased
proliferation in cells transfected with SETBP1 compared with
mock-transfected cells was observed using the MTS assay (Figure
4A); furthermore, total cell counts and cell viability were deter-
mined by Nucleo Counter and confirmed with the Trypan Blue
method (data not shown). These results confirmed the higher cell
counts and better viability of cells transfected with SETBP1
compared with cells transfected with the empty vector. Similar
results were obtained with the 32Dcl3 cell line (Figure 4A). In
addition, we observed reduced PP2A activity in both HEL and
32Dcl3 cells transfected with SETBP1.
To confirm our hypothesis that SETBP1 inhibits PP2A through
SET, SET was down-regulated by SET-specific siRNAs (supplemen-
tal Figure 4). We observed that the effects of SETBP1 on cell
proliferation and PP2A activity were impaired in both HEL and
32Dcl3 cells after SET knockdown (Figure 4B).
SETBP1 forms a complex including SET and PP2A
It has been reported that SETBP1 interacts with SET and that the
region of SET that binds to SETBP1 is different from the PP2A
inhibitory region. Accordingly, it was postulated that SETBP1-SET
heterodimers interact with PP2A.21 However, no experimental
evidence to confirm this hypothesis has been provided yet. To
determine whether SET interacts simultaneously with SETBP1 and
PP2A, coimmunoprecipitation assays were carried out in HEK293
cells, transfected or not with SETBP1-GFP. PP2A and SET
coimmunoprecipitated with SETBP1, suggesting the existence of a
SETBP1–SET-PP2A complex. Preclearing of SET using anti-SET
antibodies bound to Sepharose-protein G inhibited the coimmuno-
precipitation of PP2A and SET with SETBP1, indicating that PP2A
interacts with the SETBP1-SET heterodimer through SET and that
SETBP1 and PP2A do not directly interact with each other.
Interestingly, we found that the coimmunoprecipitated PP2A was
phosphorylated on its tyrosine-307 (Figure 5). Taken together,
these results suggest that the SETBP1-SET heterodimer interacts
with PP2A forming a SETBP1–SET-PP2A complex in which the
presence of SET is critical.
Prevalence of SETBP1 overexpression in AML
To study the prevalence of SETBP1 overexpression and its
prognostic value in AML, we quantified the expression of SETBP1
in a series of 192 patients with AML at diagnosis, correlated these
values with the French-American-British classification, and cytoge-
netic and molecular markers, and studied the prognostic relevance
of this aberration. Patient characteristics are presented in Table 1,
and box-plots show the SETBP1 expression levels in supplemental
Figure 5. Although patients were treated with different schedules,
all received regimens based on anthracycline and cytarabine as
Figure 3. Comparison of the PP2A and SET protein levels by
Western blot between patient samples and normal donors. Phos-
phorylation on tyrosine-307 of PP2A is also assessed. The K562 cell line
was used as a positive control for SET overexpression and hyperphos-
phorylation of Y-307 of PP2A. N1-N5 indicates normal controls; R,
patient sample at relapse; PT, patient sample after treatment; D, patient
sample at diagnosis; and C, K562 cells as positive control.
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induction therapy. High-dose cytarabine, and autologous or allo-
genic stem cell transplantation when possible, were used as
consolidation therapy. All patients provided informed consent.
SETBP1 was overexpressed in 53 of 192 patients (27.6%). The
prevalence in cytogenetic prognostic groups was as follows: good,
24% (7 of 29); intermediate, 18.5% (17 of 92); and poor, 40.8%
(29 of 71). We found genetic aberrations associated with SETBP1
overexpression: monosomy 7 (P  .007), chromosome 18 aberra-
tions (P  .031), and EVI1 overexpression (P  .001). An inverse
correlation was observed between SETBP1 overexpression and
normal karyotype (P  .010), and NPM1 mutations in patients
with wild-type FLT3 (P  .045; Table 2).
Figure 4. Effect of SETBP1 on cell proliferation and PP2A activity. (A) MTS assays showing the effect of ectopic SETBP1 expression alone or with SET-specific siRNAs on
the growth of HEL and 32Dcl3. (B) PP2A phosphatase assay in HEL and 32Dcl3 cells either not transfected or expressing the empty vector as a control, SETBP1 alone, or
SETBP1 with SET down-regulated by SET-specific siRNAs.
Figure 5. PP2A interacts with SET-SETBP1 heterodimer but not directly with SETBP1. Cell extracts expressing SETBP1-GFP (lanes 2 and 3) were immunoprecipitated
with anti-GFP followed by Western blotting with anti-SET and anti-PP2A. Cell extract without SETBP1-GFP expression was used as negative control (lane 1). One of the cell
extracts expressing SETBP1-GFP was precleared of SET using anti-SET antibodies bound to Sepharose-protein G before the immunoprecipitation (lane 2).
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Prognostic impact of SETBP1 overexpression in AML
Clinical follow-up data were available for 168 patients (supplemen-
tal Table 2), 91 men and 77 women, with a median age of 56 years.
Median OS of the global cohort was 31.7 (95% confidence interval,
21.5-41.9 weeks; supplemental Figure 5). As expected, significant
differences in OS according to age, cytogenetic group, and
complete remission rate were found in this series (P  .01). In
addition, we found significant differences in OS between patients
with and without SETBP1 overexpression (P  .01; supplemental
Figure 6). Interestingly, the prognostic impact of SETBP1 overex-
pression was particularly evident in patients older than 60 years
(Figure 6A). Univariate analysis showed that only complete
remission (P  .01) and SETBP1 overexpression (P  .015), but
not cytogenetic group (P  .059), were significant in OS in the
group of patients older than 60 years. Multivariate analysis
demonstrated that SETBP1 overexpression was an unfavorable
independent factor associated with OS in elderly patients with
AML (Table 3).
Only 121 of this series of 168 patients received induction
therapy. We also found significant differences in age, cytogenetic
group, and complete remission (data not shown) in this series.
When we investigated the prognostic impact of SETBP1 overexpres-
sion in this cohort, we found that patients with SETBP1 overexpres-
sion had significantly worse OS (P  .016) and EFS (P  .015;
Figure 6B). We found no differences in DFS (P  .366). Sixty-
six patients of this series were included in the intermediate
cytogenetic risk group, and 47 had normal karyotype. Patients with
SETBP1 overexpression had a worse OS than those without
(median, 26 vs 45.9 weeks); however, differences were not statisti-
cally significant, probably because of the small number of SETBP1
cases. A worse outcome in DFS (median, 20.9 vs 61.4 weeks) and
EFS (median, 23.3 vs 40 weeks) was also observed.
To analyze the molecular events that could lead to SETBP1
overexpression in the AML cases, we performed a bioinformatic
analysis of the proximal promoter of SETBP1. We identified
several hypothetical binding sites for transcription factors previ-
ously implicated in leukemia, such as GATA1, GATA2, EVI1,
HMG-1, or AP-1 (supplemental Table 3). Moreover, there is a CpG
island within the putative proximal promoter of SETBP1 that spans
1812 bp and could lead to the hypothetical epigenetic deregulation
of SETBP1 in cases with overexpression of this gene. Interestingly,
6 of the 7 retroviral insertion sites described by Ott et al20 are
located in a region of 200 bp (40513701-40513912), where this
CpG island is located (40512982-40514793).
Discussion
We report here a novel mechanism of transformation in acute
myeloid leukemia. We first investigated a t(12;18)(p13;q12) involv-
ing ETV6 in a patient with AML. Functionally significant fusions
could not be detected. Knowing that SETBP1 (18q12) was close to
the translocation breakpoint, and taking into account that ectopic
expression of oncogenes is a mechanism involved in leukemia, we
postulated that overexpression of SETBP1 could be the major event
in this case. Indeed, SETBP1 was overexpressed at diagnosis and in
the posttreatment samples of the patient (Figure 1). As activation of
SETBP1 expression by retroviral integration in hematopoietic
progenitor cells had been reported to confer a growth advantage
leading to clonal expansion20 and we could establish that SETBP1
overexpression was a recurrent molecular event with poor prognos-
tic impact in AML, we decided to investigate the leukemogenic
mechanism of overexpression of this gene. In this paper, we show
that SETBP1 overexpression protects SET from protease cleavage,
increasing the amount of full-length SET protein, and leading to the
formation of a SETBP1–SET-PP2A complex that results in PP2A
inhibition, and therefore promotes the proliferation and expansion
of leukemic cells.
SETBP1 encodes a protein of 1542 amino acids and 170 kDa,
localized predominantly in the nucleus, as we have confirmed in
this study (supplemental Figure 2B). The physiologic function as
well as the molecular mechanism by which SETBP1 acts remains
unknown. The protein contains a region homologous to the
dimerization domain of SKI, and a SET-binding region, although
Table 1. Clinical and molecular characteristics of a series
of 192 patients with AML
Characteristic No. (%)
Sex
Male 99 (53)
Female 88 (47)
No data 5
Age
Less than 60 years 92 (50.3)
More than 60 years 91 (49.7)
No data 9
Complete remission
No 47 (36.7)
Yes 81 (63.3)
No data 64
Diagnosis
AML-M0 21 (10.9)
AML-M1 35 (18.2)
AML-M2 38 (19.8)
AML-M3 7 (3.6)
AML-M4 33 (17.2)
AML-M5 36 (18.8)
AML-M6 12 (6.3)
AML-NOS 10 (5.2)
Secondary AML
No 130 (83.3)
Yes 26 (16.7)
No data 36
Cytogenetic group
Good 29 (15)
Intermediate 92 (48)
Poor 71 (37)
SETBP1 overexpression
No 139 (72.4)
Yes 53 (27.6)
WT1 overexpression
No 22 (16)
Yes 115 (84)
No data 55
EVI1 overexpression
No 132 (76.7)
Yes 40 (23.3)
No data 20
NPM1 mutated
No 18 (37.5)
Yes 30 (62.5)
No data 144
FLT3-ITD
No 99 (79.2)
Yes 26 (20.8)
No data 67
AML indicates acute myeloid leukemia.
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the functional significance of these interactions has not been
determined.21 The protein SET (I2PP2A/TAF-I) inhibits PP2A
through the phosphorylation of the PP2Ac tyrosine-307.24 Indeed,
SET is overexpressed in multiple solid tumors25 and in chronic
myeloid leukemia where its correlation has been demonstrated with
the expression and oncogenic activity of BCR-ABL, leading to
PP2A inhibition.23
Here, we demonstrate that SETBP1 overexpression increased
the 39-kDa full-length SET, probably because the SETBP1-SET
interaction protects SET from protease-mediated cleavage. As a
consequence, we detected a decrease in the 27-, 24-, and 20-kDa
SET forms (Figure 2A). It has been reported that SET inhibits
the DNase activity of the tumor suppressor NM23-H1 and that
the cleavage of SET by Granzyme A during the cytotoxic
T lymphocyte-induced apoptosis releases NM23-H1 from inhi-
bition and triggers NM23-H1 to translocate into the nucleus,
where it nicks the DNA.26,27 Interestingly, the cleavage of SET
by Granzyme A generates 3 polypeptides with similar molecular
weight to those we detected. Although more studies are needed
to clarify this point, our results suggest a possible role for
SETBP1 impairing the cleavage of SET by Granzyme A in the
apoptosis caspase-independent pathway induced by cytotoxic
T lymphocytes. This could point to a novel defense mechanism
in leukemic cells.
PP2A is a major protein phosphatase implicated in many cell
processes,28-32 and its loss of function has been associated with cell
Table 2. Association between SETBP1 overexpression and clinical and genetic parameters in 192 patients with AML at diagnosis
No. of cases SETBP1, no. (%) No. SETBP1, no. (%) P
SETBP1 192 139 (72.4) 53 (27.6)
Sex 187 136 51 .511
Male 99 70 (70.7) 29 (29.3)
Female 88 66 (75) 22 (25)
Age 183 136 47 .219
Less than 60 years 92 72 (78.3) 20 (21.7)
More than 60 years 91 64 (70.3) 27 (29.7)
Complete remission 128 180 50 .196
No 47 33 (70.2) 14 (29.8)
Yes 81 65 (80.2) 16 (19.8)
Secondary AML 156 247 56 .354
No 130 101 (77.7) 29 (22.3)
Yes 26 18 (69.2) 8 (30.8)
Prognostic group 192 139 53 .006*
Good 29 22 (76) 7 (24)
Intermediate 92 75 (82.5) 17 (18.5)
Poor 71 42 (59.2) 29 (40.8)
Cytogenetic group 192 139 53
Normal karyotype .010*
Yes 63 53 (84) 10 (16)
No 128 85 (66.4) 43 (33.6)
Trisomy 8 .943
Yes 18 13 (72.2) 5 (27.8)
No 163 119 (73) 44 (27)
Chromosome 18 aberrations .031*
Yes 11 5 (45.4) 6 (54.6)
No 169 127 (75) 42 (25)
Monosomy 7 .007*
Yes 27 14 (51.9) 13 (48.1)
No 155 119 (76.8) 36 (23.2)
der(7q) .318
Yes 16 10 (62.5) 6 (37.5)
No 166 123 (74.1) 43 (25.9)
WT1 overexpression 137 108 29 .345
No 22 19 (86.7) 3 (13.6)
Yes 115 89 (77.4) 26 (22.6)
EVI1 overexpression 172 126 46 .001*
No 132 108 (81.8) 24 (18.2)
Yes 40 18 (45) 22 (55)
MDS1EVI1 overexpression 152 109 43 .012*
No 138 103 (74.6) 35 (25.4)
Yes 14 6 (42.9) 8 (57.1)
NPM1 mutated and FLT3 wt 32 28 4 .014*
No 12 8 (66.7) 4 (33.3)
Yes 20 20 (100) 0 (0.0)
FLT3-ITD 125 100 25 .760
No 99 78 (78.8) 21 (21.2)
Yes 26 22 (84.6) 4 (15.4)
AML indicates acute myeloid leukemia.
*Significant values.
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transformation.33,34 Because SET is a potent inhibitor of PP2A and
SETBP1 overexpression alters the level of SET, we analyzed the
effect of SETBP1 overexpression on PP2A. In addition to the
previously reported SETBP1-SET and SET-PP2A complexes, we
demonstrated the formation of a SETBP1–SET-PP2A heterotri-
meric complex, in which PP2A is phosphorylated and, therefore,
inhibited (Figure 5). Our results suggest that this is the molecular
mechanism by which PP2A is inhibited in patients with SETBP1
overexpression and AML because PP2A and SETBP1 did not
interact in the absence of SET (Figure 5). Interestingly, we only
detected the full-length SET form in the immunoprecipitate,
indicating that the shorter processed forms are not present in the
SETBP1–SET-PP2A complex. It has been reported that these forms
conserve their inhibitory activity of PP2A, but it remains unclear
whether this activity is similar to that of full-length SET35; our
results suggest that the processed forms may have lower PP2A
inhibitory activity and that SETBP1 may increase the inhibition of
PP2A by protecting the full-length SET protein, and permitting its
interaction with PP2A.
Moreover, SET is a key modulator of DNA replication,
chromatin remodeling and gene transcription,36,37 differentiation,38
and cell-cycle regulation.39 We postulate that the protecting role
that SETBP1 overexpression plays on SET might reflect changes in
the expression patterns of genes whose acetylation depends on the
presence of the full-length SET protein because 39 kDa SET, but
not the processed forms, has been reported to inhibit histone
acetylation and to bind to HuR, which stabilizes immediate early
gene mRNAs.25,36,40 Our results showed that the SETBD region is
critical for this function (Figure 2B); therefore, the interaction of
SETBP1 and SET could have other effects apart from the inhibition
of PP2A.
To assess the prevalence and the prognostic significance of
SETBP1 overexpression, we analyzed the expression of this gene in
192 patients with AML at diagnosis, and we found that SETBP1
overexpression was a recurrent event in AML, accounting for
27.6% of all cases. Our results show that SETBP1 overexpression
predicts shorter OS and that the impact on prognosis is especially
significant in patients older than 60 years (Figure 6A). AML is a
disease of the elderly, with a median age at diagnosis more than
60 years. However, the gradual improvements achieved in the last
2 decades have been mainly focused on the group of patients
younger than 60 years, whereas there has been no change in the OS
of patients older than 60 years, probably because of both patient-
and disease-specific factors, although this subgroup represents
two-thirds of the total number of cases.41 It is therefore important to
identify genetic markers that could predict prognosis in this
subgroup of patients, as well as to advance our knowledge of
disease biology to develop novel targeted therapies. Our data
suggest that SETBP1 overexpression could distinguish 2 subgroups
of AML elderly patients; furthermore, it could be a predictive factor
Figure 6. SETBP1 overexpression and cumulative survival in AML. (A) Kaplan-Meier analyses of OS for SETBP1 in the series of age-stratified 168 patients with AML, and
clinical follow-up data available. Patients older than 60 years with SETBP1 overexpression showed a poorer outcome compared with patients with no SETBP1 overexpression.
(B) Kaplan-Meier analyses of OS, DFS, and EFS for SETBP1 overexpression in a series of 121 patients with AML and clinical follow-up data available who received induction
therapy (note that this group of 121 patients is included in the previous series of 168 patients in panel A).
Table 3. Multivariate analysis of clinical and biologic variables in
the group of patients with AML older than 60 years
Variable Subset
Hazard ratio (95%
confidence interval) P
Complete remission No/yes 1/0.218 (0.110-0.430) .001
SETBP1 overexpression No/yes 1/2.311 (1.173-4.553) .015
AML indicates acute myeloid leukemia.
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of response to PP2A activators, such as FTY720, which has been
proposed as a future alternative for treating blast-crisis chronic
myeloid leukemia and Philadelphia-positive acute lymphocytic
leukemia.42
Although multivariate analysis confirmed the negative prog-
nostic impact of SETBP1 overexpression in our series, it was
associated with other poor prognostic markers, such as mono-
somy 7 and EVI1 overexpression. AML is a multistep genetic
disease, and the activation of SETBP1 may cooperate with
additional mutations to induce leukemia.20 In the patient with
t(12;18), we found no FLT3, NPM1, or JAK2 mutations,
although trisomy 19 was observed in the blast cells of the patient
as a secondary event that would cooperate in the progression of
the disease. Moreover, posttreatment samples showed overex-
pression of SET and ETV6, which could act synergistically with
SETBP1 overexpression (supplemental Figure 3). The mecha-
nisms by which SETBP1 is overexpressed in the series analyzed
remain unknown. However, bioinformatic analysis of the puta-
tive promoter region of SETBP1 allowed us to identify several
transcription factors previously implicated in leukemia (supple-
mental Table 3); so we postulate that their deregulation could
promote SETBP1 overexpression. FISH analysis suggests that
the breakpoint in the patient with the t(12;18) is located
upstream to the transcription start site of SETBP1, close to the
retroviral insertion sites described by Ott et al.20 Moreover, 6 of
the 7 retroviral insertion sites described in that paper are located
in a region of 200 bp (40513701-40513912), where we have
found a CpG island (40512982-40514793). Taken together, this
suggests that this is an important region for the transcriptional
regulation of the SETBP1 gene and that epigenetic aberrations
could be another mechanism of SETBP1 overexpression in
patients with AML without 18q aberrations. Further studies to
confirm this and to analyze the promoter region of SETBP1 are
in progress.
In conclusion, we report a novel mechanism of leukemic
transformation. Overexpression of SETBP1 promotes an increase
in full-length SET levels, impairing the phosphatase activity of the
tumor suppressor PP2A through the formation of a SETBP1–SET-
PP2A complex, and promoting the proliferation of cells (Figure 7).
Besides, we demonstrate that SETBP1 overexpression protects
SET from protease cleavage, which could have important effects on
both the histone acetylation inhibitory activity of SET and Gran-
zyme A–mediated caspase-independent apoptosis induced by cyto-
toxic T lymphocytes. Furthermore, deregulation of SETBP1 by
translocations or other unknown mechanisms seems to play a
crucial role in the leukemic transformation of AML. We have
shown that SETBP1 overexpression is a recurrent molecular event
with independent prognostic value in AML, especially in the
subgroup of elderly patients. Further research into the physiologic
function of this gene will contribute to a better understanding of the
multiple steps that give rise to AML.
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